Benjamin Altheimer

Benjamin Altheimer is a Senior Scientist at Entact Bio since September 2023, with previous experience as a Senior Scientist at Civetta Therapeutics from September 2021 to September 2023, where responsibilities included biophysics leadership for pipeline targets. At Skyhawk Therapeutics, from January 2020 to August 2021, Benjamin evaluated and developed biophysical tools for RNA splicing targets. During a doctoral candidacy at Harvard University from September 2012 to August 2019, Benjamin focused on novel in vitro biophysical assays under Professor Xiaowei Zhuang and published significant research findings. Educational background includes a PhD in Biophysics from Harvard University and a Bachelor's degree in Chemistry and Physics from Oberlin College.